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Abstract:  Cancer cluster investigations rarely receive significant public health resource 
allocations due to numerous inherent challenges and the limited success of past efforts. In 
2008, a cluster of polycythemia vera, a rare blood cancer with unknown etiology, was 
identified  in  northeast  Pennsylvania.  A  multidisciplinary  group  of  federal  and  state 
agencies, academic institutions, and local healthcare providers subsequently developed a 
multifaceted research portfolio designed to better understand the cause of the cluster. This 
research agenda represents a unique and important opportunity to demonstrate that cancer 
cluster investigations can produce desirable public health and scientific outcomes when 
necessary resources are available. 
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1. Introduction 
In 2004, four cases of a rare blood cancer called polycythemia vera (PV) were found in people living 
on the same rural road near the borough of Tamaqua in northeast Pennsylvania. This finding led the 
Pennsylvania Department of Health (PADOH) to review cancer cases reported to the Pennsylvania 
Cancer Registry from the three counties (Carbon, Luzerne, and Schuylkill) surrounding the Tamaqua 
area. PADOH found that the overall cancer rate in the tri-county area was similar to that in other parts 
of the state, but there were more PV cases than expected [1]. In October 2006, PADOH asked the 
Agency for Toxic Substances and Disease Registry (ATSDR) to help further study the patterns of PV 
in the tri-county area. 
PV is a myeloproliferative neoplasm (MPN) of the bone marrow characterized by an overproduction 
of erythrocytes and often other blood cells. Previously known as myeloproliferative disorders (MPDs), 
the MPNs include essential thrombocytosis (ET), primary idiopathic myelofibrosis (IM), and chronic 
myelogenous leukemia (CML). PV has no known cause and is estimated to occur in 1 of every 100,000 
people each year [2]. The median age of diagnosis for PV is approximately 60 years, and males account 
for  slightly  more  than  half  (58%)  of  the  cases  [3].  In  2004,  an  acquired  point  mutation  in  the  
Janus-activated kinase-2 (JAK2) gene was discovered which occurs in >95% of all PV patients and 
approximately 50% of those with ET or IM, but not in other cancers [4]. The resultant JAK2 V617F 
mutation in the bone marrow stem cell confers a loss of auto-inhibitory control and an overproduction Int. J. Environ. Res. Public Health 2010, 7                 
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of the various cell-types. Although PV is not considered a hereditary disease, familial clustering of 
cases has been reported [5,6]. In addition, three recent studies [7-9] all demonstrated that the malignant 
clone  containing  the  JAK2  mutation  is  strongly  associated  with  a  particular  germ  line  haplotype 
encompassing the JAK2 gene. This haplotype is defined by specific single nucleotide polymorphisms 
(SNPs) which occur at frequencies of 5–41% in European populations. Before the discovery of the 
JAK2 mutation, PV was diagnosed using a complex series of clinical and laboratory parameters. In 
2008, the World Health Organization (WHO) updated the existing 2001 diagnostic recommendations 
for MPNs by including the JAK2 mutation as a major diagnostic criterion for PV. This change resulted 
in a simplified and more straightforward diagnostic rubric using a disease-specific biomarker, and was 
used by ATSDR to validate cases in their investigation [10]. 
The goals of the ATSDR investigation were to: (1) locate all cases of PV in Carbon, Luzerne, and 
Schuylkill counties, (2) confirm the diagnosis of the PV cases using medical records and testing for the 
JAK2 mutation, and (3) describe the characteristics of the suspected PV cases. As a result of the 
investigation, ATSDR identified a statistically significant (p < 0.001) cluster of 15 PV cases at the 
nexus of Carbon, Luzerne, and Schuylkill counties [11]. As a group, the confirmed PV cases did not 
report any employment, leisure activities, or other factors that were different from those reported by 
participants  who were found not to have PV. The investigation also found that nearly half of the 
confirmed PV cases had not been reported to the Pennsylvania Cancer Registry, and that a third of the 
participants reported to the registry during this period with a physician’s clinical diagnosis of PV did 
not  satisfy  the  2001  or  2008  WHO  PV  criteria.  The identification of the PV cluster is  important 
because it is the first reported for any MPN, a group of diseases with unknown etiology. The presence 
of  numerous  potential  environmental  exposures  in  the  cluster area—and the absence of any other 
apparent  cause—create  the  possibility  that  external  factors  contributed  to  the  cluster.  In  addition, 
serious questions were raised about the completeness and homogeneity of PV and other MPN cases 
reported to cancer registries, resulting in part from the recent addition of the JAK2 mutation to the 
diagnosis criteria. In August 2008, ATSDR and PADOH convened an expert panel in Philadelphia, 
composed of medical researchers, environmental scientists, and public health professionals to review 
the  findings  and  recommend  future  studies  that  would  help  explain  the  origin  of  the  cluster  and 
advance general knowledge about PV and other MPNs. This report summarizes the resultant research 
portfolio developed by ATSDR and the objective and rationale for each project. 
2. Results and Discussion  
The  PV  expert  panel  identified  4  major  research  areas:  epidemiology,  genetics/biomarkers, 
toxicology, and environmental analysis. Within these four areas, 13 separate projects were discussed. 
All the projects have the potential to provide new information about PV, but differ in scope. Some are 
specific  to  the  PV  cluster  in  the  Tamaqua  area  while  others  involve  broader  geographic  areas  of 
Pennsylvania and/or other states or answer questions related to MPN etiology and reporting. ATSDR 
and PADOH prioritized the research proposals by evaluating the comments of panel members, the 
scope and potential benefits of each proposal, and the resources and time required to complete each 
project. Efforts were made to identify which institutions or agencies could most effectively address 
each  project.  As  a  result,  11  studies  were  selected  for  the  PV  research  portfolio  along  with  five Int. J. Environ. Res. Public Health 2010, 7                 
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additional non-research activities that address environmental data collection, community involvement 
and physician education (Table 1). 
Table 1. Polycythemia vera research projects, duration, and partners. 
Project  Period  Partner 
Epidemiologic Studies     
Case-control study in the cluster area  2 years 
Drexel University School of  
Public Health 
Comparative epidemiologic study in western Pennsylvania  2 years 
University of Pittsburgh  
Cancer Institute 
PV and MPN surveillance in Pennsylvania  3 years 
Pennsylvania Department of Health 
(PADOH) 
Patterns of MPN diagnosis, reporting, and care  3 years  Geisinger Clinic 
Prospective study of JAK2-positive non-MPN  
in the tri-county area 
3 years  Geisinger Clinic 
Enhancement of physician reporting of hematologic cancers in the 
CDC National Program of Cancer Registries 
3 years 
Centers for Disease Control  
and Prevention (CDC) 
Geospatial analysis of MPN residences  3 years  ATSDR 
Genetic and Biomarker Studies     
Gene profiling study  3 years  Mt. Sinai School of Medicine 
JAK2 screening in the cluster area  1 year  ATSDR 
JAK2 prevalence study  1 year  Geisinger Clinic 
Tissue bank for cluster-area MPN patients  3 years  MPD-Research Consortium 
Toxicology Studies     
Bone marrow toxicological assay  3 years  Mt. Sinai School of Medicine 
Environmental Studies     
Environmental exposure assessment and data inventory  2 years  ATSDR 
McAdoo superfund site outflow testing  2 years 
Pennsylvania Department of 
Environmental Protection (PADEP) 
Residential testing  2 years 
Cogeneration water monitoring testing  2 years 
Community Involvement/Education Activities     
Community action committee (CAC)  2 years  Henry S. Cole & Associates 
Physician education  3 years  Geisinger Clinic 
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2.1. Epidemiologic Studies 
 
2.1.1. Case control study (Drexel University School of Public Health) 
 
Objective: To identify risk factors associated with the development of PV in the cluster area. 
Methods/Rationale:  While  the  initial  ATSDR  study  looked  for  commonalities  among  the 
individuals confirmed to have PV, it was not designed to identify a potential cause for the cluster. The 
expert panel believed it was important to formally assess possible risk factors for PV in the tri-county 
area.  Such  a  study  is  challenging  because  both  the  cause  for  the  MPNs  and  the  time  frame  for 
development of disease after either a cancer-producing exposure or occurrence of the JAK2 mutation 
are unknown. The study will focus on a variety of external causes, especially those related to the 
environment,  and  hereditary  or  genetic  influences.  Persons  with  confirmed  PV  from  the  original 
ATSDR study will be enrolled, as well as those more recently identified, and will have appropriate 
non-ill control groups. The specific methods for conducting the case-control study are currently in 
development.  The  study  is  expected  to  be  multiyear  and  to  have  an  environmental  
sampling component. 
 
2.1.2. Comparative epidemiologic study (University of Pittsburgh Cancer Institute) 
 
Objective: To explore the patterns of PV and other MPNs in another area of Pennsylvania with 
similar characteristics to the PV cluster area. 
Methods/Rationale: A number of problems were identified in the initial ATSDR study regarding the 
accuracy of PV reports to the cancer registry. Many reported cases were found not to have the disease, 
and a number of confirmed cases that had not been reported to the registry during the time period of 
interest were found. These problems are unlikely to be unique to the tri-county area, and make it 
difficult to compare data from that area to those found in other parts of Pennsylvania or elsewhere in 
the country. It is possible that other locations also have excess rates of PV and MPNs, especially those 
that have similar characteristics to the tri-county area of northeast PA. If they do, it might help identify 
possible causes, and if they do not, it might help focus investigations in the cluster area on unique 
features  of  that  location.  The  investigators  will  reproduce  the  original  ATSDR  study  in  another  
multi-county area in Pennsylvania that is largely rural, has a similar population size and demographics, 
and shares many other features with the cluster location. The primary task is to locate all PV cases 
diagnosed from 2001 to 2007 in the selected area, including those not reported to the Pennsylvania 
Cancer Registry, and verify the diagnoses using 2008 WHO criteria. Genetic testing will be offered, if 
necessary, to confirm the MPN diagnosis.  
 
2.1.3. PV and MPN surveillance (PADOH) 
 
Objectives: To (1) continue surveillance of PV and other MPNs reported to the Pennsylvania Cancer 
Registry  in  both  the  cluster  area  and  in  other  areas  of Pennsylvania, (2) verify the diagnosis  and Int. J. Environ. Res. Public Health 2010, 7                 
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evaluate the reporting frequency of newly diagnosed cases, and (3) provide logistical and technical 
assistance to other research partners working in Pennsylvania.  
Methods/Rationale: 
1. PV Surveillance—PADOH will assess and classify cases of PV reported to the cancer registry 
from the tri-county area since the joint PADOH/ATSDR survey was conducted in 2005. Other counties 
in Pennsylvania reporting high rates of PV compared to the state average will also be evaluated. The 
PV  diagnosis  will  be  confirmed  using  2008  WHO  guidelines  by  reviewing  medical  records  and 
offering a JAK2 analysis, if needed. Non-reported cases in the tri-county area will be identified through 
regional hematologists/oncologists.  
2. MPN Surveillance—The MPNs represent  an inter-related series  of diseases  that may have a 
common origin, and CML, ET, and IM have not yet been evaluated in the tri-county area. Since there is 
an apparent excess of PV in the area, the other MPNs may be similarly elevated. Persons identified in 
the Pennsylvania Cancer Registry since 2001 with any of these three diseases will be assessed through 
questionnaires and will be offered genetic testing, if necessary, for validation of their diagnosis. Data in 
the registry related to these disorders from other areas of the Commonwealth will also be reviewed. 
3.  Logistical/Technical  Support—PADOH  will  assist  other  research  partners  by  providing 
community outreach and support, local clinical laboratory services (where available), and logistical and 
technical assistance. This will include coordinating with community leaders; providing educational and 
informational  materials  to  local  residents;  and  offering  clinical  services  to  PV  research  partners, 
including blood draws, specimen storage and transfer to outside laboratories. PADOH will also assist 
research partners with data needs with respect to the cancer registry and other state databases.  
 
2.1.4. Patterns of MPN diagnosis, reporting, and care (Geisinger Clinic)  
 
Objective: To determine the patterns of diagnosis, treatment and reporting for MPN patients by 
physicians in northeast Pennsylvania.  
Methods/Rationale: Health records of MPN patients residing in Carbon, Luzerne and Schuylkill 
Counties who are being seen by Geisinger physicians will be scanned for the presence of an MPN 
diagnosis.  The  percentage  of  these  patients  that  are  tested  and  that  carry  a  known  MPN-related 
mutation will be determined. The primary treatment modalities and the registry reporting status of each 
patient will be documented. Education and/or information about new diagnostic tests and guidelines 
for MPNs will be provided to physicians of MPN patients. The results will be of value in future tumor 
registry studies and supplement similar work by PADOH (see 2.1.3.).  
 
2.1.5. Prospective study of JAK2-positive persons without MPN or with mild MPN in the tri-county 
area (Geisinger Clinic) 
 
Objectives: To fully characterize subjects who carry the JAK2 mutation but either do not meet the 
2008 WHO diagnostic criteria for a MPN, or meet the diagnostic criteria but have mild disease (i.e., 
not requiring therapy), and to follow the natural progression of the disease to a clinically active MPN 
requiring therapy. Int. J. Environ. Res. Public Health 2010, 7                 
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Methods/Rationale: Screening for the JAK2 mutation was offered to cluster area residents as a 
public  service  in  late  2009.  A  number  of  JAK2-positive  individuals  were  identified  who  were 
asymptomatic or had minimal evidence of disease. These individuals have been asked to participate in 
this study. It is anticipated that no more than 20 individuals will be eligible. Each participant will 
require an initial consultation and a thorough medical history and physical exam. Periodic assessments, 
including a complete blood count and quantitative JAK2 assay, will be performed at least every 6 
months  to  monitor  progression  of  the  mutation  burden.  Enrolled  subjects  who  are  found  to  have 
evidence of PV or another MPN requiring treatment will no longer be eligible for participation in this 
study. They will be treated according to standard procedures for the clinical management of these 
conditions. They may also be invited to participate in other MPN-related clinical trials, as appropriate.  
 
2.1.6.  Enhancement  of  physician  reporting  of  hematologic  cancers,  including  PV,  in  the  CDC 
supported National Program of Cancer Registries (Centers for Disease Control and Prevention) 
 
Objective: To evaluate and enhance the reporting of PV and other hematologic cancers to central 
cancer registries.  
Methods/Rationale: The validity of data collected and reported by central cancer registries depends, 
in part, upon the completeness and accuracy of data reporting. While hospitals routinely report cancer 
cases,  reporting  from  outpatient  locations  varies  widely.  Thus,  cancers  such  as  MPNs,  which  are 
diagnosed  in  an outpatient setting, are often under-reported. Cancer registries  are not  equipped to 
validate or confirm diagnoses, and rely upon the medical practitioner to accurately identify reportable 
cases. Changes in the diagnostic definition of a particular cancer created by the discovery of new 
techniques, such as biomolecular or genetic markers, are reflected in cancer registry data only to the 
extent they are adopted by physicians. Because these changes in medical practice take place over a 
period of time and through a consensus process within the medical community, registry data during this 
transition includes cases diagnosed using different disease definitions. This lack of homogeneity may 
affect measurement of disease trends. The CDC’s National Program of Cancer Registries will fund a 
select number of cancer registries to improve and enhance reporting of PV and other hematopoietic 
diseases diagnosed in physician offices. The work will focus on evaluating current MPN diagnosis and 
reporting  practices,  increasing  physician  awareness  of  reporting  requirements  and  processes,  and 
building infrastructure at the physician and state health department level for electronic reporting of 
hematologic cancers from hematology practices.  
 
2.1.7. Geospatial analysis of MPN residences (ATSDR) 
 
Objective: To continue the geospatial analysis of the PV cluster, assess the impact of newly found 
cases and evaluate current and historic residences of PV cases, other MPN cases, and asymptomatic 
JAK2-positive  individuals  with  respect  to  potential  environmental  risk  factors  identified  by  the  
on-going work. 
Methods/Rationale:  Newly-found  cases  of  PV  and  other  MPNs,  along  with  non-MPN  
JAK2-positive individuals identified in the screening project (see 2.2.2.) will be added to the existing Int. J. Environ. Res. Public Health 2010, 7                 
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database. The results of the environmental testing and other relevant studies will be used to evaluate 
associations between PV cases and potential exposure sources, assess specific agents and exposure 
pathways, and conduct comparative analyses with other potential cluster areas. This work will involve 
the use of standard geospatial tools, space-time analyses, and non-traditional methods such as those 
used in the initial cluster identification [11].  
 
2.2. Genetic and Biomarker Studies 
 
2.2.1. JAK2 screening in the cluster area (ATSDR)  
 
Objective: To conduct JAK2 screening as a community service in and around the PV cluster area to 
identify individuals carrying the JAK2 mutation.  
Methods/Rationale: Residents who have lived in the tri-county study area for at least one year were 
eligible to participate in the screening. Blood-draw clinics were established in three locations in and 
around  the  cluster  area  during  two  separate  screening  events  in  August  and  October  of  2009. 
Specimens  were  shipped  overnight  to  the  molecular  diagnostic  laboratory  at  Mt.  Sinai  School  of 
Medicine for JAK2 analysis. Specimens were first screened qualitatively for the JAK2 mutation using 
a one-step amplification refractory mutation system polymerase chain reaction (PCR) method. The 
assay has a sensitivity of 0.01% of JAK2 allele in a wild-type background and a specificity of >99.5%. 
All positives were re-tested using a real-time PCR quantitative assay to confirm the qualitative result 
and determine the JAK2 allele burden. Individuals who tested positive for the JAK2 mutation were 
invited to participate in a follow-up study which will monitor their JAK2 burden and hematologic 
status every 6 months for a three year period (see section 2.1.5.). 
 
2.2.2. JAK2 prevalence study (Geisinger Clinic)  
 
Objectives:  To  (1)  systematically  evaluate  the  prevalence  of  the  JAK2  mutation  in  healthy 
individuals from the cluster area and from parts of Pennsylvania outside the tri-county area, and (2) 
genotype DNA from a subset of the patients for two JAK2 susceptibility SNPs.  
Methods/Rationale:  Geisinger  Clinic  is  part  of  the  Geisinger  Health  System,  which  provides 
primary care to residents of over 40 counties in central and eastern Pennsylvania, with over 2.6 million 
people living in the primary service area. Geisinger has implemented a robust electronic health record 
system (EPIC
®) which manages all aspects of patient care and treatment, and a biobank (MyCode
®) 
with over 23,000 consented participants and 56,000 blood specimens available for research purposes. 
The EPIC
® and MyCode
® systems will be used to generate a random sample of 2,500 specimens from 
within  the  cluster  area  and  6,000  specimens  from  outside  the  tri-county  area  which  are  
age- and gender-adjusted to the cluster area. Demographic and health data will be available for each 
specimen donor, including the results of any additional laboratory tests that have been performed (e.g., 
complete blood count, hematocrit, hemoglobin, lactate dehydrogenase, erythropoietin).  
1. JAK2 Prevalence. The JAK2 V617F TaqMan RT-PCR Assay (Applied Biosystems, Carlsbad, 
CA) will be used to identify the JAK2 mutation in DNA extracted from the selected blood specimens. Int. J. Environ. Res. Public Health 2010, 7                 
 
 
1147 
The method will be validated against the nested allele-specific PCR assay used in the JAK2 screening 
project (see section 2.2.1.), and all specimens testing positive will be sent to the Mt. Sinai molecular 
diagnostic laboratory for validation and quantification of the JAK2 mutation. 
2. JAK2 Susceptibility Haplotype. Three recent studies [7-9] all demonstrated that the malignant 
clone containing the JAK2 mutation was strongly associated with a particular germ line haplotype that 
encompassed the JAK2 gene and was defined by SNPs. This susceptibility haplotype can be defined by 
the  SNPs  rs12343867  (risk  allele  C;  non-risk  T)  and  a  tagged  SNP  rs12340895  (risk  allele  G;  
non-risk C). The reported frequencies of these SNPs/haplotypes vary slightly among European derived 
populations, with homozygous minor allele frequencies of 5% to 7% and heterozygous frequencies of 
38%  to  41%.  Genotyping  2500  cluster-area  specimens  and  2500  controls  (ensuring  at  least  100 
homozygotes in each group) provides sufficient power (>80%; alpha = 0.05) to detect a difference in 
homozygous  frequencies  of  ~6%  to  ~8%,  and  heterozygous  difference  from  ~40%  to  ~44%.  The 
frequency of the susceptibility haplotype and association of the haplotype with presence of the somatic 
JAK2 mutation will be compared in the cluster area and control area specimens.  
 
2.2.3. Gene profiling study (Mt. Sinai School of Medicine) 
 
 Objective:  To  analyze  PV  cluster-area  patient  specimens  and  a  control  population  from  other 
geographic areas by gene profiling analyses and Genome-Wide SNP Association Platform (SNAP) 
arrays to detect genetic precursors to MPNs and/or unique signatures specific to the MPN population in 
the Tamaqua area.  
Methods/Rationale: Total  RNA and genomic DNA will be prepared from granulocytes isolated 
from PV patients from the study area and PV patients geographically distant from the study area. The 
Affymetrix  Human  Genome  U133  plus  array  will  be  used  with  normalized  data  obtained  from 
GeneChip®  Operating  Software  analysis  of  the  Affymetrix  Human  Genome  U133  plus  chips.  A 
Significance  Analysis  of  Microarrays  using  the  Institute  for  Genomic  Research  MultiExperiment 
Viewer software package will be performed to determine probes that show the highest differential 
expression between study area and non-study area PV samples. The lists of up- or down-regulated 
genes in study area and non-study area PV specimens will be determined and p-values calculated. 
 
2.2.4. Tissue bank for cluster-area MPN patients (MPD-Research Consortium, New York)  
 
Objective: To collect and store tissue samples from MPN patients in the cluster area.  
Methods/Rationale:  The  MPD-Research  Consortium  (MPD-RC)  has  established  an  MPD  tissue 
bank at the New York City Blood Center. The MPD-RC will provide support for patient recruitment 
and evaluation; tissue specimen collection, storage, and shipping; and other activities as specified by 
the  tissue  bank  protocol.  Tissue  specimens  collected  from  up  to  140  living  patients  and  10  
post-mortem MPN patients will include bone marrow aspirate, bone marrow biopsy, toenail clippings, 
spleen cells, and blood. Other tissues, and tissues from patients without an established MPN diagnosis, 
may be collected if deemed appropriate by the tissue bank or the attending physician. The collected Int. J. Environ. Res. Public Health 2010, 7                 
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samples will be used to conduct laboratory investigations to help define mechanisms involved in the 
pathophysiology of these disorders, possible causes of the cluster, and potential treatments. 
2.3. Toxicology Studies 
2.3.1. Bone marrow toxicological assay (Mt. Sinai School of Medicine) 
 
Objective:  To  develop  a  physiological  in  vitro  assay  for  stem  cell-derived  progenitor  cells  to 
evaluate potential toxins present in the cluster area that may cause PV.  
Methods/Rationale: An in vitro cell culture system that captures essential features of the in vivo 
erythroid micronucleus genotoxicity assay will be used to identify environmental agents in the study 
area that might increase hematopoietic DNA damage. Ten pure toxic compounds will be selected from 
the potential contaminants in the study area based on their ability to cause DNA damage in mammalian 
cells and the likelihood of past human exposure in the cluster area. The effects of agents which induce 
or inhibit metabolic activation/detoxification processes (i.e., P450 enzymes) will also be evaluated. 
Three known genotoxicants that test positive in the in vivo erythroid micronucleus assay will serve as 
positive  controls  for  this  study,  specifically  BCNU  (1,3-bis[2-chloroethyl]-1-nitrosourea),  MNNG  
(N-methyl-N*-nitro-N-nitrosoguanidine),  and  MMS  (methyl-methane  sulfonate)  [12].  The  selected 
compounds or controls will be added to normal human stem/progenitor cells for 1h, 4h, 12h or 24h at 
various  concentrations.  The  Comet  assay  and  micronucleus  test  will  be  used  to  screen  for  DNA 
damage caused by environmental mutagens. These assays will be repeated on 10–15 normal donors for 
each toxic compound. Archived specimens from PV patients in the study area will be evaluated for 
DNA irregularities in the in vitro culture caused by selected environmental agents. 
2.4. Environmental Studies 
2.4.1. Environmental exposure assessment data inventory (ATSDR) 
 
Objective:  To  compile  an  integrated  database  of  all  federal,  state,  and  other  relevant  data  and 
documents pertaining to hazardous waste sites, human exposures, environmental testing, and industries 
or businesses that release toxic materials in the identified cluster area.  
Methods/Rationale:  ATSDR  will  create  a  comprehensive  database  that  combines  the  extensive 
collection of data and other geospatial resources from the tri-county and identified cluster area into a 
useful research tool, and will allow researchers to access data by site, substance, exposure pathway, and 
time period. This data warehouse will include: 
  Environmental data, including types and locations of industries and hazardous waste sites; land 
use and cover; water use and distribution; air emission inventories and sources of air pollution; 
waste management information; and environmental sampling information for chemicals and 
radionuclides released into air, water, soil, and biota. 
  Topographic data, including roads, water features, and base maps that define legal boundaries 
and serve as reference points. 
  Demographic data, including the age, race, sex, education, and income of the population in the 
tri-county area. Int. J. Environ. Res. Public Health 2010, 7                 
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  Health outcome data, including PV and MPN incidence and surveillance data, JAK2 screening 
and prevalence data, and other health conditions identified during the PV investigations.  
While  the  data  warehouse  is  designed  primarily  to  study  potential  relationships  between 
environmental exposures, PV and the JAK2 mutation in selected portions of the tri-county area, the 
information will also be useful for the study of other diseases in the tri-county area and as a reference 
for other areas with similar problems.  
 
2.4.2. Environmental testing (Pennsylvania Department of Environmental Protection) 
 
Objectives: To obtain comprehensive environmental data regarding (1) water outflows from the 
McAdoo  Superfund  site;  (2)  indoor  and  outdoor  contaminants  at  current  and  past  residences  of 
confirmed PV patients and other residential properties in the cluster area; and (3) water monitoring at 
three waste coal cogeneration plants in the study area. 
Methods/Rationale:  
1. McAdoo Outflow Testing. Water and sediment samples will be collected from a minimum of 20 
different locations at the McAdoo Associates site to provide data that describes the surface water and 
groundwater  outflow  to  the  south.  The  locations  will  be  sampled  for  volatile  organic  compounds 
(VOCs), semi-volatile organic compounds (SVOCs), heavy metals, polychlorinated biphenyls (PCBs) 
and radioactivity at least two times over the period of 1 year to reflect seasonal variations.  
2. PV Residence Testing. Drinking water quality, soil, indoor dust, and residential radon levels will 
be tested at the current and past residences of confirmed PV patients and at a number of other sites in 
the cluster area. Samples will be tested for VOCs, SVOCs, heavy metals, PCBs, herbicides, pesticides 
and radioactivity.  
3. CoGeneration Water Monitoring Testing. Water samples will be collected from various locations 
at three waste coal CoGeneration plants in the study area. The selected sites will be sampled for VOCs, 
SVOCs, heavy metals, PCBs, radioactivity (gross alpha & beta), and other water chemistry parameters 
(e.g.,  nitrate/nitrite,  fluoride,  sulfates,  alkalinity)  on  two  separate  occasions  to  reflect  
seasonal variations.  
2.5. Community Involvement/Education Activities 
2.5.1. Community Action Committee (Henry S. Cole & Associates) 
 
Objective:  To  form  a  Community  Action  Committee  which  will  represent  the  cluster-area 
communities in communications with the various environmental, public health, and MPN research 
groups and organizations.  
Methods/Rationale: The Community Action Committee will be built around an existing core group 
of  local  residents  with  the  intension  of  giving  a  voice  to  the  various  community  interests.  The 
committee will conduct regular meetings; produce reports, minutes and other documents to assist the 
community  in  understanding  technical  information  on  relevant  environmental  health  issues.  The 
committee  will  also  provide  informational  support  for  MPN  patients  and  their  families,  including Int. J. Environ. Res. Public Health 2010, 7                 
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rosters  of  area  hematologists  and  other  specialists,  access  to  treatment  and  clinical  trials,  and  an 
interface with government organizations on key patient issues.  
 
2.5.2. Physician education (Geisinger Clinic) 
 
Objective:  To provide training and education, including CME-eligible lectures, to physicians in 
northeast Pennsylvania on diagnosis, treatment, and reporting of PV and other MPNs.  
Methods/Rationale: The educational programs will occur on a bi-monthly basis at local hospitals 
(i.e., grand rounds) and other venues convenient for local practitioners. The materials developed will 
improve reporting of hematological cancers and raise awareness of the increased PV incidence in the 
cluster area. The educational programs will be available to representatives from other medical groups 
in Pennsylvania and other states and will be presented at a minimum of one regional and one national 
conference within the two year project period. 
 
2.6. Oversight and Management (ATSDR) 
 
Objective: To provide oversight and technical support for all PV research projects.  
Methods/Rationale: ATSDR  will encourage and initiate collaboration between partners, provide 
technical details or data required by partners to perform their work, and coordinate meetings with 
community representatives. 
3. Conclusions  
Hundreds of suspected cancer clusters are reported to state and federal public health agencies each 
year, the majority of which are evaluated and resolved quickly because they include a wide range of 
cancers, involve a small number of reported cases, lack potential exposure source(s) or exposure data, 
or because the occurrence of cases is within a normal range for the country [13]. For the few clusters 
that are investigated, the results are nearly always disappointing to the community since, even if the 
cluster can be verified, the cause usually cannot. Accordingly, state and federal public health agencies 
apply  their  limited  resources  to  competing  or  more  urgent  priorities  with  a  greater  chance  for  a 
meaningful outcome. The current cluster investigation is thus unique in that it has the full support of 
both federal (ATSDR) and state (PADOH) public health agencies. Moreover, instead of the single 
potential  exposure  source  commonly  associated  with  cancer  clusters,  the  PV  cluster  requires 
assessment of myriad potential environmental influences–hazardous waste sites, industrial emissions 
and  waste,  and  naturally-occurring  radiation  sources–in  addition  to  possible  inherited  genetic  risk 
factors. Finally, and most importantly, the investigation is being supported by significant financial and 
technical resources. This support is rare in cancer cluster studies, and allows for a comprehensive 
research portfolio that will, regardless of whether the specific cause of the cluster can be determined, 
result in benefits to local residents, MPN and cancer patients elsewhere, and the medical research 
community.  These  benefits  include  the  community  JAK2  screening  and  follow-up  study, 
comprehensive testing of residential properties, the MPN patient support group, ready access for local 
MPN  patients  to  clinical  trials,  and  increased  local  physician  awareness  of  MPN  diagnosis  and Int. J. Environ. Res. Public Health 2010, 7                 
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treatment.  Also,  even  if  environmental  agents  cannot  be  linked  to  the  PV  cluster,  the  enhanced 
evaluations  may  result  in  additional  clean-up  or  regulatory  actions  and  improvements  in  local 
environmental quality. More far-reaching impacts are the evaluation of other potential high-rate areas 
of  PV  in  Pennsylvania;  improvements  in  the diagnosis  and reporting of MPNs to  national  cancer 
registries (and thus a better understanding of the true incidence of these cancers); the determination of 
the JAK2 mutation prevalence in the general population; a better understanding of the etiology and 
inter-relationship of MPNs, along with associated genetic risk factors, which may lead to improved 
treatments  and  prevention  strategies;  improved  geospatial  tools  and  methods  for  cancer  cluster 
analysis; and the environmental exposure data inventory, which will be a valuable resource to the 
current PV research groups and others studying similar environmental cancer links.  
This multifaceted research partnership is a unique and important opportunity to demonstrate that 
cancer  cluster  investigations  can  produce  desirable  public  health  and  scientific  outcomes  if  the 
necessary resources are available. 
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